Financial Reports
Related Searches:
Filter by:
301 - 315 of 676 results
July 21, 2010
Antivirals lead the way, but EU challenges could hurt future revenues
Read More »
July 15, 2010
Recently launched products generated sales of $2.4 billion, 21% of total sales, including A(H1N1) pandemic vaccines.
Read More »
June 11, 2010
Commercial manufacturing revenues were up 5% in the quarter to $142.2 million.
Read More »
May 5, 2010
Total contract revenue for the quarter was $38.9 million (-10%).
Read More »
May 4, 2010
Biopharmaceutical revenues were $14.5 billion in the quarter, up 44%. Established product sales were $2.9 billion in the quarter (+73%).
Read More »
May 4, 2010
Singulair sales were $1.2 billion (+10%). Remicade sales were $674 million (+30%).
Read More »
April 30, 2010
Specialty pharmaceutical sales increased 10% to $907.3 million in the quarter.
Read More »
April 29, 2010
U.S. and International sales increased 11% to $3.1 billion and $1.7 billion, respectively.
Read More »
April 29, 2010
Early development revenues were $205.0 million (+7%).
Read More »
April 28, 2010
Growth in the quarter was driven by pandemic flu vaccine sales. Total vaccine sales were $2.1 billion, including $1.1 billion of H1N1 vaccine sales.
Read More »
April 27, 2010
Growth in the quarter was driven by the Specialty Injectable Pharmaceuticals segment, with strong U.S. sales of the generic oncolytic oxaliplatin and Precedex, Hospira's proprietary sedation agent.
Read More »
April 27, 2010
Development segment revenue was $323.8 million (-3%) and income from operations was $36.8 million, compared to $62.6 million in 1Q09.
Read More »
April 27, 2010
Income from operations was $26.8 million in the quarter.
Read More »
301 - 315 of 676 results
